Payment overview · 2025
General Payments
$265.99
15 reported records · 11 companies
Healthcare provider profile · identity verified
Scott K Roos, MD
Allopathic & Osteopathic Physicians|Family Medicine · LAKE ST LOUIS, MO · NPI 1770596983
Verified facts
What the public records show
CMS Open Payments records show Scott K Roos, MD received $265.99 in general payments during 2025 across 15 reported records.
Novo Nordisk Inc accounted for 25.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 15 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Arexvy, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Synthroid by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 85 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $67.95 | 25.6% | 4 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $36.17 | 13.6% | 2 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$23.74 | 8.9% | 1 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $23.74 | 8.9% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $20.43 | 7.7% | 1 | 2025 |
| Collegium Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $17.67 | 6.6% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $16.27 | 6.1% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $15.84 | 6.0% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $15.57 | 5.8% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $14.42 | 5.4% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $14.19 | 5.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $265.99 | 15 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $37.45 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $30.50 | 2 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $23.74 | 1 | 2025 |
Source payment records
|
|||||
| INCEPTIV Normalized: inceptiv |
Device | Medtronic, Inc. | $23.74 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $20.88 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $20.43 | 1 | 2025 |
Source payment records
|
|||||
| Jornay PM Normalized: jornay pm |
Drug | Collegium Pharmaceutical, Inc. | $17.67 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $16.27 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $16.27 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $15.84 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $15.57 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $15.57 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $15.29 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $14.42 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $14.19 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| AREXVY arexvy |
2025 | Arexvy | 2024 | 24 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 47 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
46 | 13 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
24 | 24 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
47 | 16 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
13 | 13 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
85 | 21 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 763 | 231 |
| Levothyroxine Sodium | Levothyroxine Sodium | 464 | 133 |
| Lisinopril | Lisinopril | 457 | 136 |
| Losartan Potassium | Losartan Potassium | 312 | 83 |
| Omeprazole | Omeprazole | 286 | 91 |
| Amlodipine Besylate | Amlodipine Besylate | 285 | 90 |
| Gabapentin | Gabapentin | 235 | 85 |
| Metformin Hcl | Metformin Hcl | 231 | 70 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 216 | 87 |
| Alprazolam | Alprazolam | 212 | 56 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 209 | 78 |
| Simvastatin | Simvastatin | 196 | 56 |
| Trazodone Hcl | Trazodone Hcl | 188 | 67 |
| Montelukast Sodium | Montelukast Sodium | 183 | 69 |
| Metoprolol Tartrate | Metoprolol Tartrate | 180 | 56 |
| Pantoprazole Sodium | Pantoprazole Sodium | 169 | 49 |
| Tamsulosin Hcl | Tamsulosin Hcl | 167 | 62 |
| Tramadol Hcl | Tramadol Hcl | 165 | 41 |
| Citalopram Hbr | Citalopram Hydrobromide | 160 | 39 |
| Metoprolol Succinate | Metoprolol Succinate | 160 | 49 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 158 | 30 |
| Zolpidem Tartrate | Zolpidem Tartrate | 148 | 35 |
| Metformin Hcl Er | Metformin Hcl | 142 | 46 |
| Hydrochlorothiazide | Hydrochlorothiazide | 134 | 40 |
| Furosemide | Furosemide | 129 | 44 |
| Pravastatin Sodium | Pravastatin Sodium | 122 | 32 |
| Meloxicam | Meloxicam | 121 | 46 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 112 | 38 |
| Sertraline Hcl | Sertraline Hcl | 105 | 34 |
| Duloxetine Hcl | Duloxetine Hcl | 91 | 28 |
| Azelastine Hcl | Azelastine Hcl | 90 | 50 |
| Ibandronate Sodium | Ibandronate Sodium | 89 | 33 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 89 | 26 |
| Eliquis | Apixaban | 85 | 21 |
| Fluticasone Propionate | Fluticasone Propionate | 83 | 28 |
| Bupropion Xl | Bupropion Hcl | 80 | 20 |
| Carvedilol | Carvedilol | 80 | 25 |
| Finasteride | Finasteride | 75 | 21 |
| Clonazepam | Clonazepam | 74 | 12 |
| Lorazepam | Lorazepam | 73 | 23 |
| Glimepiride | Glimepiride | 68 | 21 |
| Allopurinol | Allopurinol | 63 | 22 |
| Escitalopram Oxalate | Escitalopram Oxalate | 62 | 22 |
| Famotidine | Famotidine | 62 | 23 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 59 | 16 |
| Jardiance | Empagliflozin | 55 | 16 |
| Ropinirole Hcl | Ropinirole Hcl | 55 | 12 |
| Methylprednisolone | Methylprednisolone | 54 | 48 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 54 | 15 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 52 | 17 |
| Alendronate Sodium | Alendronate Sodium | 51 | 17 |
| Propranolol Hcl | Propranolol Hcl | 51 | 18 |
| Lovastatin | Lovastatin | 50 | 12 |
| Buspirone Hcl | Buspirone Hcl | 49 | 20 |
| Oxybutynin Chloride | Oxybutynin Chloride | 49 | 18 |
| Atenolol | Atenolol | 48 | 16 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 48 | 13 |
| Prednisone | Prednisone | 48 | 27 |
| Tradjenta | Linagliptin | 48 | 11 |
| Ozempic | Semaglutide | 47 | 16 |
| Potassium Chloride | Potassium Chloride | 46 | 15 |
| Synthroid | Levothyroxine Sodium | 46 | 13 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 44 | 13 |
| Diclofenac Sodium | Diclofenac Sodium | 43 | 22 |
| Amitriptyline Hcl | Amitriptyline Hcl | 42 | 13 |
| Spironolactone | Spironolactone | 41 | 13 |
| Valacyclovir | Valacyclovir Hcl | 41 | 16 |
| Sildenafil Citrate | Sildenafil Citrate | 40 | suppressed |
| Glipizide | Glipizide | 39 | 13 |
| Farxiga | Dapagliflozin Propanediol | 38 | 12 |
| Baclofen | Baclofen | 37 | suppressed |
| Myrbetriq | Mirabegron | 37 | 14 |
| Clopidogrel | Clopidogrel Bisulfate | 35 | 11 |
| Donepezil Hcl | Donepezil Hcl | 35 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 35 | suppressed |
| Mounjaro | Tirzepatide | 33 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 33 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 33 | 12 |
| Bupropion Hcl Sr | Bupropion Hcl | 32 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 31 | suppressed |
| Topiramate | Topiramate | 31 | 12 |
| Levetiracetam | Levetiracetam | 28 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 28 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 27 | suppressed |
| Xarelto | Rivaroxaban | 27 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 26 | suppressed |
| Ezetimibe | Ezetimibe | 26 | suppressed |
| Nystatin | Nystatin | 26 | 14 |
| Irbesartan | Irbesartan | 25 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 24 | 24 |
| Doxycycline Hyclate | Doxycycline Hyclate | 24 | 19 |
| Meclizine Hcl | Meclizine Hcl | 24 | 15 |
| Cephalexin | Cephalexin | 23 | 22 |
| Dicyclomine Hcl | Dicyclomine Hcl | 23 | 12 |
| Sumatriptan Succinate | Sumatriptan Succinate | 23 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 22 | suppressed |
| Fenofibrate | Fenofibrate | 22 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 22 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 22 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 22 | suppressed |
| Sucralfate | Sucralfate | 22 | 11 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 21 | 18 |
| Naproxen | Naproxen | 21 | 11 |
| Celecoxib | Celecoxib | 20 | suppressed |
| Chlorthalidone | Chlorthalidone | 20 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 20 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 20 | suppressed |
| Fluconazole | Fluconazole | 20 | 13 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 20 | suppressed |
| Torsemide | Torsemide | 20 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 20 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 19 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 19 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 19 | suppressed |
| Estradiol | Estradiol | 19 | suppressed |
| Glipizide Er | Glipizide | 19 | suppressed |
| Hydrocortisone | Hydrocortisone | 19 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 19 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 18 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 18 | suppressed |
| Ibuprofen | Ibuprofen | 18 | suppressed |
| Mupirocin | Mupirocin | 18 | 12 |
| Oxcarbazepine | Oxcarbazepine | 18 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 18 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 18 | suppressed |
| Azithromycin | Azithromycin | 17 | 16 |
| Diazepam | Diazepam | 17 | suppressed |
| Memantine Hcl | Memantine Hcl | 17 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 17 | 15 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 17 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 16 | 11 |
| Midodrine Hcl | Midodrine Hcl | 16 | suppressed |
| Ondansetron Odt | Ondansetron | 16 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 16 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 16 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 15 | suppressed |
| Bumetanide | Bumetanide | 15 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 15 | suppressed |
| Methocarbamol | Methocarbamol | 15 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 15 | suppressed |
| Pregabalin | Pregabalin | 15 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 15 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 14 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 14 | suppressed |
| Mirtazapine | Mirtazapine | 14 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 14 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 13 | 13 |
| Labetalol Hcl | Labetalol Hcl | 13 | suppressed |
| Roflumilast | Roflumilast | 13 | suppressed |
| Rybelsus | Semaglutide | 13 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 13 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 13 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 12 | suppressed |
| Lidocaine | Lidocaine | 12 | suppressed |
| Testosterone | Testosterone | 12 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 11 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Linzess | Linaclotide | 11 | suppressed |
| Metronidazole | Metronidazole | 11 | suppressed |
| Primidone | Primidone | 11 | suppressed |
| Trulicity | Dulaglutide | 11 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Verapamil Er | Verapamil Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $265.99 · 15 records | Novo Nordisk Inc | AREXVY, Cologuard Collection Kit, FANAPT, FREESTYLE LIBRE 3, GEMTESA, INCEPTIV, Jornay PM, NURTEC ODT, Ozempic, SHINGRIX, UBRELVY, VOQUEZNA, VRAYLAR, Wegovy, ZAVZPRET | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Arexvy play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error